I agree, but they've already talked about safety, immune response, affordability and PD-1. Much of this week's announcement feels like an affirmation rather than new info.
Efficacy info has been held very close, but at least we know it's arriving in December. Hopefully, the OSU schedule holds and there will be 2 sets of data dropping in. IMO, anything less than good efficacy will not go well for the SP.
Cheers
Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-53
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.9¢ | 3.8¢ | $134.8K | 3.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 1738258 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 494405 | 4 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
